Opdualag Archives -

Australian biotech Immutep’s LAG-3 checkpoint inhibitor eftilagimod alpha (efti) may not be the first drug in the class

Immutep’s LAG-3 drug ‘dramatically undervalued,’ says analyst

https://pharmaphorum.com/news/immuteps-lag-3-drug-dramatically-undervalued-says-analyst/

Bristol-Myers Squibb’s new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few

Opdualag off to a flying start, says BMS CEO

https://pharmaphorum.com/news/opdualag-off-to-a-flying-start-says-bms-ceo/

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on

Roche’s fast-growing eye drug Vabysmo set for EU approval

https://pharmaphorum.com/news/roches-fast-growing-eye-drug-vabysmo-set-for-eu-approval/

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

https://pharmaphorum.com/news/bms-gets-fda-ok-for-first-lag-3-checkpoint-inhibitor/

Opdualag